Results 161 to 170 of about 1,795 (205)

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women

Journal of clinical pharmacology, 2020
This analysis developed a population pharmacokinetic (PK) model for odanacatib, characterized demographic and concomitant medication covariates effect, and provided odanacatib exposure estimates for subjects in phase 2/3 studies. Data from multiple phase
D. Jaworowicz, S. Bihorel, S. Zajic, S. Stoch, R. Humphrey, J. McCrea, J. Stone   +6 more
semanticscholar   +1 more source

Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells

, 2020
A cross-linking agent commonly used for cancer chemotherapy is a platinum compound such as cisplatin. However, with the acquisition of cellular drug resistance and adverse side effects, the potency of cisplatin is, therefore, often tempered.
Y. Vashum, A. Kottaiswamy, Tholcopiyan Loganathan, Fathima Bushra Sheriff, S. Samuel   +4 more
semanticscholar   +1 more source

Potential Role of Odanacatib in the Treatment of Postmenopausal Intervertebral Disc Degeneration

Journal of Biomedical Nanotechnology
Odanacatib (ODN), a cathepsin K (CatK) inhibitor, is widely used for the treatment of postmenopausal osteoporosis. However, whether ODN is efficient in delaying intervertebral disc degeneration (IVDD) remaining unknown.
Peng Liu, Songqi Liu, Tiantian Gao, Zhengping Zhang, Junsong Yang, Jijun Liu, Dichen Li   +6 more
semanticscholar   +1 more source

Treatment of postmenopausal osteoporosis with odanacatib

Expert Opinion on Pharmacotherapy, 2014
The market of anti-osteoporosis drugs has been declining in recent years, possibly in part due to the publicity around adverse events observed with bisphosphonates. Also, the proportion of patients with clinical fracture who receive adequate treatment remains low. So there are still unmet needs in this field.
openaire   +2 more sources

Disposition and Metabolism of the Cathepsin K Inhibitor Odanacatib in Humans

Drug Metabolism and Disposition, 2014
Odanacatib is a selective inhibitor of the cathepsin K enzyme that is expressed in osteoclasts involved in the degradation of bone organic matrix, and is being developed as a novel treatment of osteoporosis. Odanacatib has demonstrated increases in bone mineral density in postmenopausal women and is undergoing a pivotal phase III trial. The absorption,
Kelem, Kassahun, Ian, McIntosh, Kenneth, Koeplinger, Li, Sun, Jennifer E, Talaty, Deborah L, Miller, Russell, Dixon, Stefan, Zajic, S Aubrey, Stoch   +8 more
openaire   +2 more sources

[Odanacatib (MK-0822)].

Clinical calcium, 2011
Bone homeostasis is maintained by delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. Bisphosphonates are widely used nowadays by suppressing bone resorption to treat patients with osteoporosis, which results from high bone turnover, causing excessive bone resorption phase.
Yuichi, Nagase, Sakae, Tanaka
openaire   +1 more source

Formulation and Stability of Itraconazole and Odanacatib Nanoparticles: Governing Physical Parameters

Molecular Pharmaceutics, 2009
The successful formulation of itraconazole and odanacatib into nanoparticle form with diameters of 145 and 350 nm, respectively, using rapid, block copolymer-directed precipitation is presented. These are the smallest stable nanoparticles that have been reported for these compounds.
Varun, Kumar, Lei, Wang, Mike, Riebe, Hsien-Hsin, Tung, Robert K, Prud'homme   +4 more
openaire   +2 more sources

Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects

Clinical pharmacology in drug development, 2019
Assessing risk for QTc interval prolongation in a thorough QTc study is a standard recommendation when evaluating new chemical entities. As part of the clinical development program for odanacatib, an oral selective inhibitor of cathepsin K previously in ...
J. McCrea, Kate Mostoller, C. Mahon, Chengcheng Liu, Fang Liu, S. Zajic, D. Panebianco, M. Chakravarthy, C. Brandquist, M. Gutierrez, S. Stoch   +10 more
semanticscholar   +1 more source

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

Bioorganic & Medicinal Chemistry Letters, 2008
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724. Substituting P1 and modifying the P2 side chain led to a metabolically robust inhibitor with a long half-life in preclinical species.
Jacques Yves, Gauthier, Nathalie, Chauret, Wanda, Cromlish, Sylvie, Desmarais, Le T, Duong, Jean-Pierre, Falgueyret, Donald B, Kimmel, Sonia, Lamontagne, Serge, Léger, Tammy, LeRiche, Chun Sing, Li, Frédéric, Massé, Daniel J, McKay, Deborah A, Nicoll-Griffith, Renata M, Oballa, James T, Palmer, M David, Percival, Denis, Riendeau, Joel, Robichaud, Gideon A, Rodan, Sevgi B, Rodan, Carmai, Seto, Michel, Thérien, Vouy-Linh, Truong, Michael C, Venuti, Gregg, Wesolowski, Robert N, Young, Robert, Zamboni, W Cameron, Black   +28 more
openaire   +2 more sources

Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis

Journal of Bone and Mineral Metabolism, 2014
The aim of this study was to evaluate the efficacy and safety of odanacatib (ODN) for the treatment of osteoporosis, using data in studies reported in the literature. We performed a literature search to compare the outcomes of applications of once-weekly ODN 50 mg and control.
Shi, Feng, Zhicheng, Luo, Da, Liu
openaire   +2 more sources